Deborah Elaine Wilson

Address:

1710 Wagon Gap Trl, Houston, TX 77090

VIN:

WBAVA37597NL15119

Make:

BMW

Model:

3 SERIES

Year:

2007

US Patent:

6372249, Apr 16, 2002

Filed:

Oct 24, 1994

Appl. No.:

08/327874

Inventors:

James R. Smith - Houston TX
David J. Drutz - Houston TX
Deborah R. Wilson - Houston TX
Louis A. Zumstein - Houston TX

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

A61K 9127

US Classification:

424450, 514 2, 514 12, 530350

Abstract:

The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.

US Patent:

6726907, Apr 27, 2004

Filed:

Apr 24, 2000

Appl. No.:

09/556570

Inventors:

Shuyuan Zhang - Sugar Land TX
Capucine Thwin - Seattle WA
Zheng Wu - Sugarland TX
Toohyon Cho - Philadelphia PA
Deborah R. Wilson - Houston TX
Lucetta Caston - Limerick PA

Assignee:

Introgen Therapeutics, Inc. - Austin TX

International Classification:

C12N 700

US Classification:

424 932, 4242331, 4241991, 424 936, 4352351, 4353201, 435239

Abstract:

The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

US Patent:

7445930, Nov 4, 2008

Filed:

Jul 30, 2004

Appl. No.:

10/909066

Inventors:

Shuyuan Zhang - Sugarland TX, US
Capucine Thwin - Seattle WA, US
Zheng Wu - Sugarland TX, US
Toohyon Cho - Philadelphia PA, US
Deborah Wilson - Houston TX, US
Lucetta Caston - Limerick PA, US

Assignee:

Introgen Therapeutics Inc. - Austin TX

International Classification:

C12N 15/00
A61K 39/00
A61K 39/23
A61K 39/095

US Classification:

4353201, 4241841, 4242331

Abstract:

The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

US Patent:

7510875, Mar 31, 2009

Filed:

Dec 27, 2001

Appl. No.:

10/033571

Inventors:

Shuyuan Zhang - Sugarland TX, US
Capucine Thwin - Seattle WA, US
Zheng Wu - Sugarland TX, US
Toohyon Cho - Philadelphia PA, US
Deborah Wilson - Houston TX, US
Lucetta Caston - Limerick PA, US

Assignee:

Introgen Therapuetics, Inc. - Austin TX

International Classification:

C12N 7/02
C12N 5/00
A61K 39/235
C07K 1/00
A23J 1/00

US Classification:

435329, 4242331, 435383, 530417

Abstract:

The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

US Patent:

20070155008, Jul 5, 2007

Filed:

Aug 23, 2006

Appl. No.:

11/508780

Inventors:

Shuyuan Zhang - Sugar Land TX, US
Capucine Thwin - Sugar Land TX, US
Zheng Wu - Sugar Land TX, US
Toohyon Cho - Houston TX, US
Deborah Wilson - Houston TX, US
Lucetta Caston - Limerick PA, US

Assignee:

INTROGEN THERAPEUTICS INC. - Austin TX

International Classification:

C12P 21/06
C12N 15/00

US Classification:

435320100, 435069100

Abstract:

The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

US Patent:

61334162, Oct 17, 2000

Filed:

Aug 22, 1997

Appl. No.:

8/918712

Inventors:

Deborah R. Wilson - Houston TX
Therese M. Timmons - Houston TX
Julia A. Lee - Houston TX
Brian D. Almond - Houston TX
Jack A. Roth - Houston TX

Assignee:

The University of Texas System Board of Regents - Austin TX

International Classification:

C07K 200
C07K 400
C07K 500
A61K 4500

US Classification:

530300

Abstract:

The present invention involves the identification of a factor or factors that are anti-proliferative and can be used in the treatment of cancers and other hyperproliferative disease states. The factor or factors are induced from cells follow contact of the cells with viral or plasmid expression vectors. One factor is between about 3 kDa and 300 kDa in size, while another is less than about 3 kDa in size. Both are heat stable and is resistant to both protease and nuclease treatment. Methods for purification and use of the factor also are disclosed.

US Patent:

55455638, Aug 13, 1996

Filed:

Mar 4, 1994

Appl. No.:

8/205506

Inventors:

Gretchen J. Darlington - Houston TX
Deborah R. Wilson - Houston TX
Margaret Wilde - Missouri City TX

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

C12N 1511
C12N 1512
C12N 1585

US Classification:

4353201

Abstract:

A gene sequence that encodes the human CCAAT/enhancer binding protein ("C/EBP"), and recombinant vectors that are capable of mediating the expression of the C/EBP gene are described. The gene sequence and vector can be used in methods of gene therapy to treat cancer and other diseases.